Coca-Cola Consolidated, Inc.
COKE
$214.93
+2.50%
Coca-Cola Consolidated, Inc. is the largest independent bottler of Coca-Cola products in the United States, manufacturing, marketing, and distributing a broad portfolio of sparkling and still nonalcoholic beverages — including Coca-Cola trademark brands, energy drinks, bottled water, ready-to-drink tea and coffee, enhanced water, juices, and sports drinks — across a multi-state territory, with the Nonalcoholic Beverages segment generating the overwhelming majority of revenue. Unlike The Coca-Cola Company, which owns the concentrate and brand IP, COKE is a capital-intensive distribution and manufacturing operator whose economics hinge on volume, pricing, route density, and operating leverage rather than global brand licensing. The current investor narrative centers on a dramatic re-rating: the stock has surged roughly 61% over the past year and 40% year-to-date, driven by double-digit revenue growth, gross margin near 38-40%, aggressive share repurchases that have shrunk the diluted share count from ~87 million to ~66.6 million, and a forward PE near 5.4x that suggests the market is still debating whether this is a durable margin-expansion story or a cyclical, low-multiple bottler that has simply run too far. Attention is also focused on the company's balance-sheet transformation — heavy debt repayment and buybacks have pushed reported book equity negative, distorting traditional valuation ratios — and on whether pricing power in the U.S. sparkling portfolio can offset still-beverage softness and input-cost inflation.…
COKE
Coca-Cola Consolidated, Inc.
$214.93
Investment Opinion: Should I buy COKE Today?
Rating: Hold. The core thesis is that COKE is a cash-generative, low-beta bottler with genuine operating momentum, but the absence of analyst consensus and the stock's 61.1% one-year run leave the risk/reward balanced at $210.33. With only one analyst covering the name and no published target price, the forward PE of 5.4x is a single-point estimate rather than a consensus anchor, making it difficult to argue the stock is unambiguously cheap.
Supporting evidence is nonetheless substantial: revenue grew 10.6% YoY in Q2 2026 to $2.05 billion, gross margin held at 37.9%, operating margin improved to 13.2%, TTM free cash flow reached $644.7 million (5.7% FCF yield), and diluted shares fell 23.5% to 66.65 million. The stock's 1.56x PS ratio and 13.5x EV/EBITDA are reasonable for a defensive compounder, and the 0.539 beta offers portfolio stability. However, the negative book equity and -15.3 P/B mean traditional value screens will flag the stock as uninvestable, potentially limiting institutional demand.
Key risks that could invalidate the thesis include a deceleration in revenue growth below 5%, a reversal in gross margin below 35%, or a failed roll-out of pricing actions leading to volume declines. The rating would upgrade to Buy if the forward PE remains below 6x while revenue growth stays above 8% and free cash flow exceeds $600 million, or downgrade to Sell if gross margin falls below 35% or if short interest rises above 7 days. Relative to its own history and the consumer staples sector, COKE appears fairly valued to modestly undervalued on cash flow, but the lack of coverage and negative equity warrant a cautious stance.
Sign up to view all
COKE 12-Month Price Forecast
The forward-looking view is balanced: COKE has demonstrated genuine operating momentum with double-digit revenue growth, stable margins, and strong cash generation, but the stock has already re-rated 61.1% in a year and lacks the analyst coverage needed to validate the 5.4x forward PE. The base case (50% probability) sees the stock range-bound between $200 and $230 as growth moderates and the market waits for broader coverage. The bull case (30%) requires accelerating growth and multiple expansion, while the bear case (20%) hinges on a consumer slowdown and margin compression. I would upgrade to bullish if two or more analysts initiate coverage with Buy ratings and forward EPS estimates are revised upward, and downgrade to bearish if gross margin falls below 35% or if short interest exceeds 7 days.
Bulls vs Bears: COKE Investment Factors
The bull case rests on tangible, quantifiable strengths: 10.6% revenue growth, $644.7 million in TTM free cash flow, a 23.5% reduction in diluted shares, and a forward PE of just 5.4x. These factors have driven a 61.1% one-year return with low volatility (beta 0.539), and the balance-sheet transformation is real. However, the bear case is equally substantive: negative book equity distorts valuation, analyst coverage is virtually nonexistent, short interest is elevated at 5.03 days, and the stock has already re-rated dramatically. The single most important tension is whether the 5.4x forward PE represents a genuine mispricing or reflects the market's correct assessment that earnings are cyclical and share-count-driven rather than organic. If forward earnings estimates prove accurate and sustainable, the stock is deeply undervalued; if they are stale or inflated by one-time items, the rally is vulnerable.
Bullish
- Aggressive buybacks shrink share count: Diluted shares fell from 87.16 million in Q2 2025 to 66.65 million in Q2 2026, a 23.5% reduction, mechanically boosting EPS and signaling management's confidence in intrinsic value. This capital return is a powerful per-share value driver independent of revenue growth.
- Double-digit revenue growth and margin expansion: Q2 2026 revenue grew 10.6% YoY to $2.05 billion, while gross margin held near 38% and operating margin improved to 13.2% from 12.9% a year earlier. The combination of pricing power and operating leverage is driving profit growth ahead of sales.
- Strong free cash flow and balance-sheet deleveraging: TTM free cash flow is $644.7 million, a 5.7% FCF yield on the $11.3 billion market cap, funding both buybacks and debt reduction. Interest expense fell to $30.5 million in Q2 2026 from $59.5 million in Q2 2025, reflecting rapid debt paydown.
- Attractive forward valuation: The stock trades at just 5.4x forward earnings and 1.56x sales, a steep discount to the broader consumer staples sector. Even on trailing PE of 19.8x, the multiple is reasonable given the 10.6% revenue growth and 23.5% share count reduction.
Bearish
- Negative book equity distorts valuation: Reported book equity is negative, producing a meaningless P/B of -15.3 and debt-to-equity of -4.06. This accounting artifact from heavy buybacks and debt repayment makes traditional valuation screens unreliable and could deter value-oriented institutional investors.
- Thin analyst coverage and no consensus rating: Only one analyst covers COKE, and the recommendation field is 'none' with zero EPS estimates. This lack of coverage reduces price discovery, increases volatility around earnings, and means the 5.4x forward PE may reflect information asymmetry rather than a true bargain.
- High short interest signals skepticism: Short ratio of 5.03 indicates it would take over five days of average volume to cover short positions, a relatively elevated level for a large-cap defensive stock. This suggests a meaningful cohort of investors expects the 61% one-year rally to reverse.
- Earnings quality concerns from one-time items: Q2 2026 net income of $158.8 million included a $56.2 million negative other-income item, and Q1 2026 had an $86.3 million negative adjustment. These swings make headline EPS volatile and complicate the assessment of sustainable profitability.
COKE Technical Analysis
Beta
0.54
0.54x market volatility
Max Drawdown
-24.7%
Largest decline past year
52-Week Range
$126-$220
Price range past year
Annual Return
+66.3%
Cumulative gain past year
| Period | COKE Return | S&P 500 |
|---|---|---|
| 1m | +12.5% | -1.2% |
| 3m | +16.4% | +3.4% |
| 6m | +9.9% | +7.0% |
| 1y | +66.3% | +14.4% |
| ytd | +43.4% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COKE Fundamental Analysis
Quarterly Revenue
$2.1B
2026-07
Revenue YoY Growth
+10.6%
YoY Comparison
Gross Margin
37.9%
Latest Quarter
Free Cash Flow
$644707000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COKE Overvalued?
PE
19.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant despite the strong headline numbers. The company carries negative book equity, with debt-to-equity at -4.06 and P/B at -15.3, meaning traditional solvency metrics are uninformative and the balance sheet offers little cushion. Interest expense, while reduced to $30.5 million in Q2 2026 from $59.5 million a year earlier, still consumes roughly 14% of operating income. Earnings quality is also a concern: Q2 2026 net income of $158.8 million was dragged down by a $56.2 million negative other-income item, and Q1 2026 had an $86.3 million negative adjustment, making the 7.9% net margin less predictable than it appears. Additionally, the business is capital-intensive and concentrated in a single segment (Nonalcoholic Beverages), leaving little diversification if U.S. sparkling volumes decline.
Market and competitive risks center on valuation compression and coverage gaps. The stock trades at 19.8x trailing earnings and 13.5x EV/EBITDA, which is not cheap for a bottler with 10.6% revenue growth, and the 5.4x forward PE is based on a single analyst's estimate that may be stale. With only one analyst covering the name and no consensus rating, price discovery is poor and the stock could gap violently on any earnings miss. Short interest is elevated at a 5.03 short ratio, indicating that a meaningful cohort of investors is betting against the rally. The low beta of 0.539 provides some downside protection, but the stock's 61.1% one-year gain vastly outpaced the S&P 500's 15.5%, creating vulnerability to sector rotation if defensive staples fall out of favor.
The worst-case scenario would combine a slowdown in U.S. sparkling volumes, a reversal of pricing power due to consumer trade-down, and a market re-rating of the forward PE from 5.4x to a more conservative 4.0x. In that scenario, the stock could retrace toward its 52-week low of $126.00, representing a 40.1% decline from the current $210.33. Even a milder correction to the 52-week low area would wipe out more than a year of gains. The maximum drawdown over the past 180 days was already -24.66%, showing that the stock can fall sharply even in a benign environment. Investors should size positions accordingly, as a 40% drawdown is a realistic tail risk given the lack of analyst support and elevated short interest.
FAQ
The most severe risk is financial: negative book equity and a debt-to-equity of -4.06 mean the balance sheet offers little cushion, and interest expense of $30.5 million per quarter still consumes about 14% of operating income. Second, earnings quality is volatile, with Q2 2026 net income hit by a $56.2 million negative other-income item and Q1 2026 by an $86.3 million adjustment, making the 7.9% net margin less reliable. Third, competitive and market risks include a consumer trade-down that could pressure pricing, and the stock's 61.1% one-year outperformance versus the S&P 500's 15.5% creates vulnerability to sector rotation. Fourth, company-specific risk from thin analyst coverage (one analyst, no consensus) and elevated short interest (5.03 days) could amplify volatility around earnings.
Our 12-month forecast has three scenarios: a base case (50% probability) of $200-230, assuming revenue growth moderates to 7-9% and gross margin holds near 38%; a bull case (30%) of $240-260, driven by accelerating growth, multiple expansion to 6.5-7.0x forward earnings, and new analyst coverage; and a bear case (20%) of $126-160, if a consumer slowdown compresses margins and the forward PE re-rates to 4.0x. The most likely outcome is the base case, as the company's strong free cash flow and buyback program provide a floor, but the lack of coverage and elevated short interest limit upside. Key assumptions include flat to slightly positive U.S. sparkling volumes and 3-5% pricing increases.
On cash flow and sales, COKE appears modestly undervalued: the 1.56x PS ratio and 13.5x EV/EBITDA are below the consumer staples sector average, and the 5.7% free-cash-flow yield is attractive in a low-rate environment. However, the trailing PE of 19.8x is not cheap for a bottler with 10.6% revenue growth, and the 5.4x forward PE is based on a single analyst's estimate that may be stale. The negative book equity makes P/B meaningless, so investors must rely on cash-flow metrics. Relative to its own history, the stock is near the high end of its valuation range after a 61.1% one-year gain, suggesting the market is pricing in continued execution. Fair value is likely in the $190-220 range, implying the current price is roughly fairly valued.
COKE offers a compelling risk/reward for patient, value-oriented investors, but it is not a slam-dunk. The stock trades at 5.4x forward earnings and 1.56x sales, with $644.7 million in TTM free cash flow and a 23.5% reduction in diluted shares over the past year. However, the 61.1% one-year rally means much of the easy money has been made, and the lack of analyst coverage (only one analyst, no consensus rating) introduces information risk. The biggest downside risk is a re-rating toward the 52-week low of $126, a 40% decline, if growth stalls. For investors with a 2-3 year horizon who can tolerate volatility and illiquidity, the stock is a reasonable buy on dips below $190; for short-term traders, the elevated short interest and thin coverage make it a risky momentum play.
COKE is better suited for long-term holding (minimum 2-3 years) than short-term trading. The stock's low beta of 0.539 and defensive consumer-staples nature make it a stabilizer, but the thin analyst coverage and elevated short interest (5.03 days) can cause sharp short-term swings, as evidenced by the -24.66% maximum drawdown over the past 180 days. The dividend yield of 0.77% is modest, so total return depends on capital appreciation and buybacks, which compound over time. Short-term traders may find opportunities around earnings, but the lack of liquidity and coverage makes timing difficult. A 2-3 year holding period allows the buyback program and margin expansion to play out.